Results 151 to 160 of about 1,219,886 (310)

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Building sustainable health technology assessment capacity in Ukraine. [PDF]

Int J Technol Assess Health Care
Oortwijn W, Janssen J, Filiniuk O, Sucu R, Kievit W.   +4 more
europepmc   +1 more source

Digital Educational Content for a Modern Lesson: Quality Assessment Technology

A. V. Bosov, Nataliya L. Selivanova, Yulia Yu. Pustylnik, Yulia Pustylnik   +3 more
openalex   +1 more source

The Rankine automotive system technology assessment report: Final report

, 1988
G M Thur
openalex   +1 more source

SEARCH AND DEVELOPMENT OF NEW DEPOSITS: METHODOLOGICAL APPROACH TO ECONOMIC ASSESSMENT OF APPLICATION IN THE OIL AND GAS INDUSTRY DIGITAL TECHNOLOGIES

, 2021
Р.Х. Азиева
openalex   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

The Benefit Trajectory – a framework to support innovative and beneficial technology based solutions in integrated care

International Journal of Integrated Care, 2015
Ann-Catrine Monberg, Dorthe Furstrand Lauritsen, Lena Sundby Jensen, Lars Kayser   +3 more
doaj   +1 more source

Ex-Ante Life Cycle Assessment of Emerging and Novel Technologies [PDF]

Jade Müller-Carneiro, Carla Krulikowski Rodrigues, Maria Cléa Brito de Figueirêdo, Fausto Freire   +3 more
openalex   +1 more source

Feasibility Study and Techno-Economic Assessment of Power-to-Gas (P2g) Technology Based on Solid Oxide Electrolysis (SOE)

, 2023
Katsiaryna Martsinchyk, Aliaksandr Martsinchyk, Monika Łazor, Pavel Shuhayeu, Jakub Kupecki, Anna Niemczyk, Marcin Błesznowski, J. Milewski   +7 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source